Measurement equipment distributor Transcat (NASDAQ: TRNS) announced better-than-expected revenue in calendar Q3 2026 (fiscal Q2 2027), with sales up 18% year on year to $97.09 million. Its non-GAAP profit of $0.64 per share was 42.9% above analysts’ consensus estimates.

Is now the time to buy TRNS? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Transcat delivered an above-consensus quarter, with the market responding positively to its strong sales and non-GAAP profit performance. Management highlighted robust organic growth in its calibration services, supported by both disciplined acquisitions and improved operational execution. CEO Jaime Irick credited the company’s ability to win new business and expand its customer base in regulated markets such as life sciences and aerospace as key contributors to the results. The integration of recent acquisitions, including Southeastern Biomedical Associates, further enhanced Transcat’s reach and operational leverage, driving margin expansion within the service segment.

Looking ahead, management raised its service organic revenue growth outlook, citing increased visibility from a growing pipeline and a repeatable, recurring business model. CFO Tom Barbato emphasized that improvements in sales team focus and operational initiatives give Transcat added confidence in sustaining higher growth rates. Irick also pointed to ongoing investments in Lean principles and technology, including early adoption of AI, as longer-term drivers of productivity and customer value. Management expects continued margin expansion, particularly as operational excellence initiatives mature and the company executes against new large customer opportunities.

Key insights from management’s remarks

Management attributed the quarter’s outperformance to broad-based service growth, effective business mix management, and successful integration of acquisitions, while also noting sequential improvements in distribution margins.

• Service segment momentum: Organic growth in calibration services accelerated, with management attributing gains to market share capture, strong customer retention, and successful onboarding of new clients across highly regulated end markets like life sciences and aerospace.
• M&A integration success: The recent acquisition of Southeastern Biomedical Associates was highlighted as expanding Transcat’s presence in biomedical calibration and extending its reach across the southeastern U.S., reinforcing its role as an acquirer of choice in mission-critical markets.
• Operational excellence and Lean principles: Management emphasized early-stage operational improvements, noting that immediate benefits came from volume growth and better business mix, while longer-term gains are expected from Lean initiatives and technology adoption.
• Rental channel growth: The higher-margin rental business saw strong demand, contributing to the distribution segment’s revenue growth. Management expects the rental channel to remain a key driver of future distribution margin improvement.
• Distribution margin dynamics: Distribution margins improved sequentially despite one-off headwinds from lower-margin used equipment sales. Management expects further expansion in the second half of the year as the business mix continues to shift toward rentals.

Drivers of future performance

Management’s outlook is shaped by broad-based demand, continued operational improvements, and the expectation of sustained organic growth in both services and rentals.

• Pipeline and customer wins: Management cited increased visibility from a robust pipeline and ongoing conversion of new business as supporting higher service organic growth expectations. The company believes its repeatable sales processes and high customer retention will continue to drive market share gains.
• Margin expansion strategies: Ongoing initiatives in Lean operations, pricing optimization, and business mix management are projected to drive further gross margin gains, especially in the service segment. The company expects these efforts, along with maturing relationships from recent large deals, to support profitability.
• M&A and market opportunities: Transcat intends to maintain its focus on strategic acquisitions to supplement organic growth, targeting highly regulated, high-cost-of-failure markets. Management noted that its enhanced integration processes and disciplined M&A pipeline are expected to drive synergies and expand geographic reach.

Catalysts in upcoming quarters

Looking forward, the StockStory team will be watching (1) the pace of new service customer wins and conversion of pipeline opportunities, (2) evidence of sustained margin expansion in both service and distribution segments, and (3) the successful integration and performance of recent acquisitions like Southeastern Biomedical Associates. Continued progress in operational excellence initiatives and the impact of technology adoption will also be key signposts for execution.

Transcat currently trades at $94.86, up from $89.52 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Our favorite stocks right now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.